CorMatrix® Cardiovascular, Inc. Receives FDA Approval to Expand and Enroll 20 Additional Patients in the Adult Arm of its Early Feasibility  IDE study of the Cor® TRICUSPID ECM® Valve for Pediatric and Adult Patients

CathWorks FFRangio™ System Receives National Reimbursement Approval in Japan

CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System,...

Levine Leichtman Capital Partners Sells FlexXray

Levine Leichtman Capital Partners ("LLCP"), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company FlexXray Holdings, LLC ("FlexXray" or...

Today CorMatrix® Cardiovascular, Inc. announced receiving FDA approval to expand and enroll 20 additional patients in the adult arm, including up to 4 additional cardiac surgery research and investigative centers, for its early feasibility IDE study of the Cor® TRICUSPID ECM® valve* for pediatric and adult patients. The Cor® TRICUSPID ECM® valve has been successfully implanted in the 11th patient enrolled in the expansion by Dr. Marc Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the study. The Cor® TRICUSPID ECM® valve is a next-generation, first of its kind, biologic, seamless, and stentless cardiac valve composed of extracellular matrix or ECM®.

“The most recent implant of the CorMatrix Cor® TRICUSPID valve represents an important step toward realizing an implantable, regenerating tissue-engineered heart valve. We are now broadening the study to additional centers which will greatly increase our enrollment. So far the valves are performing very well, and patients are excited to be part of this important innovation,” said Dr. Marc W Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the CorMatrix® Cor® TRICUSPID IDE safety and feasibility clinical trial.

“CorMatrix® is very excited to expand enrollment of the adult arm of its FDA early feasibility IDE study for the Cor® TRICUSPID ECM® valve. This is just one step closer to ultimately providing biologic valve technology to an ever-expanding patient need. The Cor® TRICUSPID ECM® valve is the first of its kind that provides a new treatment option. As a result, we are very pleased to receive the approval from the FDA to expand the number of study patients and centers,” said Edgar Rey, President & CEO, CorMatrix® Cardiovascular, Inc.

*Cor® TRICUSPID ECM® valve is an investigational device and not commercially available.

spot_img

DON'T MISS

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.